Khaitan & Co advised Alembic in relation to acquisition of balance 40% stake in Aleor, a joint venture company of Alembic and Orbicular Pharmaceutical Technologies Private Limited, thereby making Aleor a wholly owned subsidiary of Alembic.
| NO | HEADINGS | DETAILS |
| 1. | Sector | Pharmaceuticals – Dermaceuticals |
| 2. | Announcement Date | 29 March 2022 (Stock Exchange disclosure of Alembic Pharmaceuticals Limited)
|
| 3. | Execution Date | 28 March 2022 (Share Purchase Agreement) |
| 4. | Completion Date | 29 March 2022 |
| 5. | Name of Client | Alembic Pharmaceuticals Limited (“Alembic”)
|
| 6. | Target, Target Country | Aleor Dermaceuticals Limited, India
|
| 7. | Target Description | Aleor Dermaceuticals Limited (“Aleor”) is engaged in the business of developing, manufacturing and selling of pharmaceutical (dermatology) products for global markets has product offerings across cream, gel, ointment, shampoo, lotion, solutions, sprays, foams, microsponge and nanoparticulate platform-based products. |
| 8. | Deal Description | Advised Alembic in relation to acquisition of balance 40% stake in Aleor, a joint venture company of Alembic and Orbicular Pharmaceutical Technologies Private Limited, thereby making Aleor a wholly owned subsidiary of Alembic. |
| 9. | Total Consideration | Confidential
|
| 10. | Team Members | The core deal team comprised of Bhavik Narsana (Partner) and Rutvi Shrimankar (Senior Associate) |
| 11. | Role of Firm | Advised Alembic in relation to the drafting, reviewing, negotiating, and finalizing various transaction documents and generally advising on various legal issues. |
| 12. | Press coverage | Stock Exchange Disclosure
Alembic Pharma buys out partner stake in Aleor Dermaceuticals | The Economic Times
Alembic Pharma acquires 100% stake in Aleor Dermaceuticals | moneycontrol |
